BioCardia Inc (BCDA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.89-2.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · BCDA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -35.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
BCDA — litigation filed
Dated 2026-09-21
Other Events. As previously disclosed, on August 19, 2026, BioCardia, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The NASDAQ Stock Market, LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the minimum price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)…
Why it matters: FDA minutes can clarify whether Helix has a path to clearance. The company said it was waiting for the final minutes.
Watch forFDA minutes support a follow-on submission. BioCardia files it with advice that may enable the De Novo path.
Also watch forFDA minutes do not back the De Novo path, or BioCardia says it will not file a follow-on submission.
Why it matters: BioCardia reported $4.1 million in cash and runway into 2027. New cash and burn figures can show whether that runway still holds.
Worry ifThe November 11 report shows cash above $4.1 million. It says runway into 2027 remains intact.
Less concerning ifThe report shows cash below $4.1 million or says the company needs new funding before 2027.
Why it matters: A signed deal would turn the stated licensing effort into a concrete business step. The company has named these tools for heart therapy delivery.
Supportive ifBioCardia announces a signed license or partnership for Helix or Heart3D. It names the partner and gives clear terms.
Worry ifBioCardia reports no signed deal by its next two quarterly updates, or says talks have ended.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$274 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $668 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,754 loss on $10,000 · 47.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.